PharmaCyte Biotech, Inc. 10-Q

Item 5. Other Information . None. Item 6. Exhibits. Exhibit No. Description Location 10.1 † Amendment No. 3, dated as of October 14, 2020, to Executive Compensation Agreement between Gerald W. Crabtree and the Company Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 16, 2020. 31.1 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith 31.2 Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith 32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002. Filed herewith 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002. Filed herewith 101. Interactive Data Files for the Company’s Form 10-Q for the period ended October 31, 2020 Submitted herewith. † Indicates a management contract or any compensatory plan, contract or arrangement. 34 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. PharmaCyte Biotech, Inc. December 11, 2020 By: /s/ Kenneth L. Waggoner Kenneth L. Waggoner Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) December 11, 2020 By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Principal Accounting Officer) 35